The Lake Wobegon effect: Are all cancer patients above average?

Milbank Quarterly

Volumn 91, Issue 4, 2013, Pages 690-728

  Wolf, Jacqueline H ^a   Wolf, Kevin S ^b  

^a OHIO UNIVERSITY   (United States)

^b Kevin Wolf and Associates   (United States)

Author keywords

end of life care; hospice; NSCLC treatment; physician patient communication

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; PEMETREXED;

ANEMIA; ARTICLE; BLISTER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EARLY CANCER; FATIGUE; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPICE CARE; HOSPICE PATIENT; HUMAN; INTESTINE INJURY; KIDNEY INJURY; LEUKOCYTE; LIVER INJURY; LOSS OF APPETITE; LUNG INJURY; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL SPECIALIST; MEDICAL STUDENT; NARRATIVE; NAUSEA; OPTIMISM; OVERALL SURVIVAL; PATIENT CARE PLANNING; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STOMACH INJURY; TERMINAL CARE; TERMINALLY ILL PATIENT; THROMBOCYTE COUNT; UNITED STATES; VOMITING; WHOLE BODY RADIATION;

END-OF-LIFE CARE; HOSPICE; NSCLC TREATMENT; PHYSICIAN/PATIENT COMMUNICATION;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; NEOPLASMS; PALLIATIVE CARE; PHYSICIAN-PATIENT RELATIONS; TERMINAL CARE; TREATMENT OUTCOME;

EID: 84890303312     PISSN: 0887378X     EISSN: 14680009     Source Type: Journal    
DOI: 10.1111/1468-0009.12030     Document Type: Article

References (66)

1. Adjuvant! Online. n.d. Adjuvant! Online: Decision Making Tools for Health Care Professionals. Available at www.adjuvantonline.com (accessed July 18, 2013).
2. Altekruse, S.F., C.L. Kosary, M. Krapcho, et al., eds. 2010. Cancer of the Lung & Bronchus (Including Non-Small-Cell and Small-Cell Lung Cancer Combined). SEER Cancer Statistics Review, 1975-2007. Available at http://seer.cancer.gov/csr/1975-2007/browse-csr.php?section=15&page= sect-15-table.10.html and http://seer.cancer.gov/csr/1975-2007/browse-csr.php? section=15&page=sect-15-table.14.html (accessed May 28, 2013).
3. Antoniou, D., K. Kyprianou, G.P. Stathopoulos, et al. 2005. Response of Radiotherapy in Brain Metastases and Survival of Patients with Non-small Cell Lung Cancer. Oncology Reports 14: 733-36.
4. Arriagada, R., B. Bergman, A. Dunant, T. Le Chevalier, J.-P. Pignon, and, J. Vansteenkiste,. 2004. Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. New England Journal of Medicine 350: 351-60.
5. Baile, W.F., G.A. Glober, R. Lenzi, E.A. Beale, and, A.P. Kudelka,. 1999. Discussing Disease Progression and End-of-Life Decisions. Oncology 13: 1021-31.
6. Barton, R., 2008. Inoperable Brain Metastases from Non-small Cell Lung Cancer: What Part Does Whole Brain Radiotherapy Play in Standard Treatment? Thorax Journal 63: 1-2.
7. Bodenheimer, T.S., and, K. Grumbach,. 2009. Understanding Health Policy: A Clinical Approach. New York: McGraw-Hill.
8. Bonomi, P., K.M. Kim, D. Fairclough, et al. 2000. Comparison of Survival and Quality of Life in Advanced Non-Small-Cell Lung Cancer Patients Treated with Two Dose Levels of Paclitaxel Combined with Cisplatin versus Etoposide with Cisplatin: Results of an Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology 18: 623-31.
9. Boxer, H., and, S. Snyder,. 2009. Five Communication Strategies to Promote Self-Management of Chronic Illness. Family Practice Management 6 (5): 12-16.
10. Cassel, C.K., and, J.A. Guest,. 2012. Choosing Wisely: Helping Physicians and Patients Make Smart Decisions about Their Care. JAMA 307 (17): 1801-2.
11. CDC (Centers for Disease Control and Prevention), National Center for Health Statistics. 2010. United States Life Tables, 2006 and National Vital Statistics Reports. June 28 (all males from table 2, all females from table 3, white females from table 6).
12. Christakis, N.A., and, E.B. Lamont,. 2000. Extent and Determinants of Error in Doctors' Prognoses in Terminally Ill Patients: Prospective Cohort Study. BMJ 320: 469-72.
13. Comis, R.L., 2005. The Current Situation: Erlotinib (Tarceva®) and Gefitinib (Iressa®) in Non-small Cell Lung Cancer. Oncologist 10: 467-70.
14. Connor, S.R., B. Pyenson, K. Fitch, C. Spence, and, K. Iwasaki,. 2007. Comparing Hospice and Nonhospice Patient Survival among Patients Who Die within a Three-Year Window. Journal of Pain Symptom Management 33: 238-46.
15. DeAngelis, L.M., J.-Y. Delattre, and, J.B. Posner,. 1989. Radiation-Induced Dementia in Patients Cured of Brain Metastases. Neurology 39: 789-96.
16. Douillard, J.-Y., R. Rosell, M. De Lena, et al. 2006. Adjuvant Vinorelbine plus Cisplatin versus Observation in Patients with Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A Randomized Controlled Trial. Lancet 7: 719-27.
17. Fruh, M., E. Rolland, J.-P. Pignon, et al. 2008. Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 26: 3573-81.
18. Gatzemeier, U., A. Pluzanska, A. Szczesna, et al. 2007. Phase III Study of Erlotinib in Combination with Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial. Journal of Clinical Oncology 25: 1545-52.
19. Genentech. 2013. Tarceva Fact Sheet. Available at http://www.gene.com/ download/pdf/tarceva-prescribing.pdf (accessed May 28, 2013).
20. Gervais, R., G. Robinet, C. Clément-Duchêne, et al. 2013. Pemetrexed and Carboplatin, and Active Option in First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Phase II Trial. Lung Cancer 80: 185-90.
21. Goldberg, S.W., J.L. Mulshine, D. Hagstrom, and, B.S. Pyenson,. 2010. An Actuarial Approach to Comparing Early Stage and Late Stage Lung Cancer Mortality and Survival. Population Health Management 13: 33-46.
22. Grønberg, B.H., R.M. Bremnes, Ø. Fløtten, et al. 2009. Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed plus Carboplatin Compared with Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 27: 3217-24.
23. Hagerty, R.G., P.N. Butow, P.M. Ellis, et al. 2005. Communicating with Realism and Hope: Incurable Cancer Patients' Views on the Disclosure of Prognosis. Journal of Clinical Oncology 23: 1278-88.
24. Hall, W.A., H.R. Djalilian, E.S. Nussbaum, and, K.H. Cho,. 2000. Long-Term Survival with Metastatic Cancer to the Brain. Medical Oncology 17: 279-86.
25. Hartocollis, A., 2009. At the End, Offering Not a Cure but Comfort. New York Times, August 19.
26. Hensing, T.A., A.H. Peterman, M.J. Schell, J.-H. Lee, and, M.A. Socinski,. 2003. The Impact of Age on Toxicity, Response Rate, Quality of Life, and Survival in Patients with Advanced, Stage IIIB or IV Nonsmall Cell Lung Carcinoma Treated with Carboplatin and Paclitaxel. Cancer Journal 98: 779-88.
27. Herbst, R.S., D. Prager, R. Hermann, et al. 2005. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined with Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 23: 5892-99.
28. Himmelstein, D.U., D. Thorne, E. Warren, and, S. Woolhandler,. 2009. Medical Bankruptcy in the United States, 2007: Results of a National Study. American Journal of Medicine 122: 741-46.
29. Himmelstein, D.U., D. Thorne, and, S. Woolhandler,. 2011. Medical Bankruptcy in Massachusetts: Has Health Reform Made a Difference? American Journal of Medicine 124: 224-28.
30. Hogan, C., J. Lunney, J. Gabel, and, J. Lynn,. 2001. Medicare Beneficiaries' Costs of Care in the Last Year of Life. Health Affairs 20: 188-95.
31. Huskamp, H.A., N.L. Keating, J.L. Malin, et al. 2009. Discussions with Physicians about Hospice among Patients with Metastatic Lung Cancer. Archives of Internal Medicine 169 (10): 954-62.
32. Keating, N.L., M.B. Landrum, S.O. Rogers, et al. 2010. Physician Factors Associated with Discussions about End-of-Life Care. Cancer 116: 998-1006.
33. Kiely, B.E., M.R. Stockler, and, M.H.N. Tattersall,. 2011. Thinking and Talking about Life Expectancy in Incurable Cancer. Seminars in Oncology 38 (3): 380-85.
34. Klabunde, C.N., A. Ambs, N.L. Keating, et al. 2009. The Role of Primary Care Physicians in Cancer Care. Journal of General Internal Medicine 24 (9): 1029-36.
35. Korenstein, D., R. Falk, E.A. Howell, T. Bishop, and, S. Keyhani,. 2012. Overuse of Health Care Services in the United States: An Understudied Problem. Archives of Internal Medicine 172 (2): 171-78.
36. Kubota, K., K. Watanabe, H. Kunitoh, et al. 2011. Phase III Randomized Trial of Docetaxel plus Cisplatin versus Vindesine plus Cisplatin in Patients with Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Group. Journal of Clinical Oncology 22: 254-61.
37. Leopold, E., 1999. A Darker Ribbon: Breast Cancer, Women, and Their Doctors in the Twentieth Century. Boston: Beacon Press.
38. Li, B., J. Yu, M. Suntharalingam, et al. 2000. Comparison of Three Treatment Options for Single Brain Metastasis from Lung Cancer. International Journal of Cancer 90: 37-45.
39. Lovenheim, S., 2009. New Study: Bankruptcy Tied to Medical Bills. Washington Post, June 4.
40. Mack, J.W., and, T.J. Smith,. 2012. Reasons Why Physicians Do Not Have Discussions about Poor Prognosis, Why It Matters, and What Can Be Improved. Journal of Clinical Oncology 30 (22): 2715-17.
41. McCarthy, E., R. Burns, R. Davis, and, R. Phillips,. 2003. Barriers to Hospice Care among Older Patients Dying with Lung and Colorectal Cancer. Journal of Clinical Oncology 21: 728-35.
42. MedPAC and Centers for Medicare & Medicaid Services. 2009. Hospice Services Payment System and Wage Index. Available at www.medpac.gov/documents/ MedPAC-Payment-Basics-09-hospice.pdf and www.cms.gov/Medicare/Medicare-Fee-for- Service-Payment/Hospice/Downloads/FY2010-Hospice-WI.zip (accessed July 20, 2012).
43. Merton, V., 1993. The Exclusion of Pregnant, Pregnable, and Once-Pregnable People (a.k.a. Women) from Biomedical Research. American Journal of Law and Medicine 19: 369-451.
44. Nieder, C., R.M. Bremnes, and, N.H. Andratschke,. 2009. Prognostic Scores in Patients with Brain Metastases from Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4: 1337-41.
45. Pignon, J.-P., H. Tribodet, G.V. Scagliotti, et al. 2008. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. Journal of Clinical Oncology 26: 3552-59.
46. Quill, T.E., 2011. Initiating End-of-Life Discussions with Seriously Ill Patients: Addressing the "Elephant in the Room." In Care at the Close of Life: Evidence and Experience, eds., S.J. McPhee, M.A. Winkler, M.W. Rabow, et al., 3-11. New York: McGraw-Hill Medical.
47. Reck, M., N. van Zandwijk, C. Gridelli, et al. 2010. Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study. Journal of Thoracic Oncology 5: 1616-22.
48. Sandler, A.B., J. Nemunaitis, C. Denham, et al. 2000. Phase III Trial of Gemcitabine plus Cisplatin versus Cisplatin Alone in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 18: 122-30.
49. Scagliotti, G.V., R. Fossati, V. Torri, et al. 2003. Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute 95: 1453-61.
50. Shepherd, F.A., J.R. Pereira, T. Ciuleanu, et al. 2005. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. New England Journal of Medicine 353: 123-32.
51. Smith, T.J., L.A. Dow, E.A. Virago, J. Khatcheressian, R. Maysuyama, and, L.J. Lyckholm,. 2011. A Pilot Trial of Decision Aids to Give Truthful Prognostic and Treatment Information to Chemotherapy Patients with Advanced Cancer. Journal of Supportive Oncology 9 (2): 79-86.
52. Smith, T.J., and, D.L. Longo,. 2012. Talking with Patients about Dying. New England Journal of Medicine 367 (17): 1651-52.
53. Smith T.J., S. Temin, E.R. Alesi, et al. 2012. American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care into Standard Oncology Care. Journal of Clinical Oncology 30: 880-87.
54. Smith-Bindman, R., J. Lipson, R. Marcus, et al. 2009. Radiation Dose Associated with Common Computed Tomography Examinations and the Associated Lifetime Attributable Risk of Cancer. Archives of Internal Medicine 169: 2078-86.
55. Soon, Y.Y., M.R. Stockler, L.M. Askie, and, M.J. Boyer,. 2009. Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Oncology 27: 3277-83.
56. Temel, J.S., J.A. Greer, A. Muzikansky, et al. 2010. Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine 363: 733-42.
57. Teutsch, C., 2003. Patient-Doctor Communication. Medical Clinics of North America 87: 1115-45.
58. Tulsky, J.A., 2005. Beyond Advance Directives: Importance of Communication Skills at the End of Life. JAMA 294 (3): 359-65.
59. U.S. Nuclear Regulatory Commission. 2011. Fact Sheet on Biological Effects of Radiation. Available at http://www.nrc.gov/reading-rm/doc- collections/fact-sheets/bio-effects-radiation.html (accessed May 28, 2013).
60. U.S. Preventive Services Task Force. 2013. Lung Cancer Screening Recommendation Statement. Available at http://www.uspreventiveservicestaskforce. org/3rduspstf/lungcancer/lungcanrs.htm (accessed August 22, 2013).
61. Waller, D., R.J. Stephens, N.H. Gower, et al. 2004. Chemotherapy for Patients with Non-small Cell Lung Cancer: The Surgical Setting of the Big Lung Trial. European Journal of Cardio-thoracic Surgery 26: 17-82.
62. Weeks, J.C., P.J. Catalano, A. Cronin, et al. 2012. Patients' Expectations about Effects of Chemotherapy for Advanced Cancer. New England Journal of Medicine 367 (17): 1616-25.
63. Wheatley-Price, P., K. Ding, L. Seymour, G.M. Clark, and, F.A. Shepherd,. 2008. Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology 26: 2350-57.
64. Zabel, A., S. Milker-Zabel, C. Thilmann, et al. 2002. Treatment of Brain Metastases in Patients with Non-small Cell Lung Cancer (NSCLC) by Stereotactic Linac-Based Radiosurgery: Prognostic Factors. Lung Cancer Journal 37: 87-94.
65. Zhang, B., A.A. Wright, H.A. Huskamp, et al. 2009. Health Care Costs in the Last Week of Life: Associations with End-of-Life Conversations. Archives of Internal Medicine 169: 480-88.
66. Zukin, M., C. Barrios, J. Pereira, et al. 2013. Randomized Phase III Trial of Single-Agent Pemetrexed versus Carboplatin and Pemetrexed in Patients with Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status 2. Journal of Clinical Oncology 31: 1-5.